Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ICJ
|
|||
| Former ID |
DNC010619
|
|||
| Drug Name |
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
|
|||
| Synonyms |
CHEMBL1086903; 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide; MLS000532882; AC1LQXAP; CBMicro_028883; Oprea1_410069; Oprea1_118265; MolPort-001-490-660; HMS2484B06; STK413461; ZINC13468414; BDBM50312579; AKOS003253125; MCULE-2070823146; SMR000140320; BIM-0028795.P001; ST50914634; N-cyclohexyl-4-(diphenylmethyl)piperazine-1-carboxamide; N-cyclohexyl-4-(diphenylmethyl)-1-piperazinecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H31N3O
|
|||
| Canonical SMILES |
C1CCC(CC1)NC(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
|
|||
| InChI |
1S/C24H31N3O/c28-24(25-22-14-8-3-9-15-22)27-18-16-26(17-19-27)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2,(H,25,28)
|
|||
| InChIKey |
IRRGBCHOFRYUCB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 401578-04-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [1] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.